Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Alefacept for Chronic Plaque Psoriasis
NCT00655564Phase 4Completed
- Sponsor
- Wake Forest University
- Start
- May 2008
- Primary completion
- Dec 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alefacept in plaque psoriasis, sponsored by Wake Forest University. Primary endpoints: Investigator Global Assessment Response at 52 weeks and 75% Reduction in Psoriasis Area and Severity Index at 52 weeks. Started May 2008; status: completed.
02
Drugs
alefacept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00655564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655564.